Compare OPXS & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OPXS | ONCY |
|---|---|---|
| Founded | 1987 | 1998 |
| Country | United States | Canada |
| Employees | 72 | N/A |
| Industry | Electronic Components | Pharmaceuticals and Biotechnology |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.5M | 98.7M |
| IPO Year | 2009 | 2002 |
| Metric | OPXS | ONCY |
|---|---|---|
| Price | $13.97 | $0.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $16.10 | $7.33 |
| AVG Volume (30 Days) | 45.4K | ★ 1.3M |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.55 | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $24,530,000.00 | N/A |
| Revenue This Year | $39.17 | N/A |
| Revenue Next Year | $0.53 | $2,505.00 |
| P/E Ratio | $61.00 | ★ N/A |
| Revenue Growth | ★ 17.63 | N/A |
| 52 Week Low | $9.74 | $0.77 |
| 52 Week High | $17.76 | $1.51 |
| Indicator | OPXS | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 60.63 | 49.11 |
| Support Level | $12.46 | $0.90 |
| Resistance Level | $13.68 | $1.06 |
| Average True Range (ATR) | 0.78 | 0.06 |
| MACD | 0.08 | 0.01 |
| Stochastic Oscillator | 78.05 | 50.87 |
Optex Systems Holdings Inc manufactures optical sighting systems and assemblies for the U.S. Department of Defense, foreign military applications, and commercial markets. Its products are installed on a variety of United States military land vehicles, such as the Abrams and Bradley fighting vehicles, light armored and security vehicles, and have been selected for installation on the Stryker family of vehicles. The company's operating segment includes Optex Systems Richardson, Applied Optics Center Dallas, and others. It generates maximum revenue from the Optex Systems Richardson segment. Some of its products include M17 Day/Thermal Periscope; DDAN / M36 Sights; Laser Protected Periscopes; Muzzle Reference Sensor, and others.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.